Literature DB >> 15970417

Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC-MS/MS with electrospray ionization: assay development, validation and application to a clinical study.

Ravi Kumar Trivedi1, Raja Reddy Kallem, Ramesh Mullangi, Nuggehally R Srinivas.   

Abstract

A simple, sensitive and specific LC-MS/MS method for simultaneous determination of rosuvastatin (RST) and fenofibric acid (FFA) was developed and validated with 500 microL human plasma using carbamazepine as an internal standard (IS). The assay procedure involved a simple one-step liquid/liquid extraction of RST and FFA and IS from plasma into ethyl acetate. The organic layer was separated and evaporated under a gentle stream of nitrogen at 40 degrees C. The residue was reconstituted in the mobile phase and injected onto X-Terra MS C-18 column (4.6 mm x 50 mm, 5.0 microm). Separation of RST, FFA and IS was achieved with a mobile phase consisting of 0.05 M formic acid:acetonitrile (45:55, v/v) at a flow rate of 0.40 ml/min. The API-3000LC-MS/MS was operated under the multiple reaction-monitoring mode (MRM) using the electrospray ionization technique. Positive ion acquisition chromatographic run was used in the present method. Nominal retention times of RST, FFA and IS were 2.35, 4.70 and 2.32 min, respectively. Absolute recovery of RST, FFA and IS was 74, 61 and 69%, respectively. The lower limit of quantification (LLOQ) of RST and FFA was 1.00 ng/ml and 0.50 microg/ml, respectively. Response function was established for the range of concentrations 1.00-50.0 ng/ml and 0.50-20.0 microg/ml for RST and FFA, respectively, with a coefficient of determination (r2) of 0.999 for both the compounds. The inter- and intra-day precision in the measurement of RST quality control (QC) samples 5, 15, 400 and 800 ng/ml, were in the range 8.93-9.37% relative standard deviation (R.S.D.) and 1.74-16.1% R.S.D., respectively. Similarly, the inter- and intra-day precision in the measurement of FFA quality control (QC) samples 0.5, 1.5, 8.0 and 15.0 microg/ml, were in the range 9.78-11.6% relative standard deviation (R.S.D.) and 0.22-17.4% R.S.D., respectively. Accuracy in the measurement of QC samples for RST and FFA were in the range 88.1-108 and 87-115%, respectively, of the nominal values. RST and FFA were stable in the battery of stability studies, viz., bench-top, auto-sampler and freeze/thaw cycles. Stability of RST and FFA was established for 1 month at -80 degrees C. The application of the assay to a clinical study confirmed the utility of the assay.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15970417     DOI: 10.1016/j.jpba.2005.05.005

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  6 in total

1.  Determination of rosuvastatin in urine by spectrofluorimetry after liquid-liquid extraction and derivatization in acidic medium.

Authors:  Victor S M Braga; Taiza P Mancilha; Ricardo J Cassella; Wagner F Pacheco
Journal:  J Fluoresc       Date:  2012-08-18       Impact factor: 2.217

2.  Effects of the PPAR-α agonist fenofibrate on acute and short-term consequences of brain ischemia.

Authors:  Thavarak Ouk; Sophie Gautier; Maud Pétrault; David Montaigne; Xavier Maréchal; Isabelle Masse; Jean-Christophe Devedjian; Dominique Deplanque; Michèle Bastide; Rémi Nevière; Patrick Duriez; Bart Staels; Florence Pasquier; Didier Leys; Régis Bordet
Journal:  J Cereb Blood Flow Metab       Date:  2014-01-08       Impact factor: 6.200

3.  Development, validation of liquid chromatography-tandem mass spectrometry method for simultaneous determination of rosuvastatin and metformin in human plasma and its application to a pharmacokinetic study.

Authors:  P Pavan Kumar; T E G K Murthy; M V Basaveswara Rao
Journal:  J Adv Pharm Technol Res       Date:  2015 Jul-Sep

4.  Development and validation of bioanalytical UHPLC-UV method for simultaneous analysis of unchanged fenofibrate and its metabolite fenofibric acid in rat plasma: Application to pharmacokinetics.

Authors:  Rayan G Alamri; Kazi Mohsin; Ajaz Ahmad; Mohammad Raish; Fars K Alanazi
Journal:  Saudi Pharm J       Date:  2016-05-26       Impact factor: 4.330

5.  Validated high-performance liquid chromatographic method for the estimation of rosuvastatin calcium in bulk and pharmaceutical formulations.

Authors:  Safwan Ashour; Soulafa Omar
Journal:  Int J Biomed Sci       Date:  2011-12

6.  A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies.

Authors:  Glenwood D Goss; Derek J Jonker; Scott A Laurie; Johanne I Weberpals; Amit M Oza; Johanna N Spaans; Charles la Porte; Jim Dimitroulakos
Journal:  J Transl Med       Date:  2016-03-31       Impact factor: 5.531

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.